← Back to headlines
Xeris Biopharma Reports Q4 Top-Line Beat and 2026 Revenue Guidance
Xeris Biopharma saw its stock rise following a strong Q4 top-line performance and positive revenue guidance for 2026.
2 Mar, 17:08 — 2 Mar, 17:08
ℹOnly 1 source covers this story
Read at source (1 outlet)
Related Stories
Bettor Wins ₱17.98M in MegaLotto 6/45 Draw on March 2
just now
iShares High Yield Systematic Bond ETF declares monthly distribution of $0.2632
6m ago
iShares BB Rated Corporate Bond ETF declares monthly distribution of $0.2275
8m ago
iShares High Yield Muni Active ETF declares monthly distribution of $0.2001
10m ago